替雷利珠单抗致免疫相关性糖尿病：病例报道与机制探讨，为临床用药敲响警钟

Tislelizumab is an anti-PD-1 immune checkpoint inhibitor that is widely used in the immunotherapy of various tumors. It may cause immune-related adverse reactions. One of the rare but serious complications is immune-related diabetes. This type of diabetes usually presents the characteristics of type 1 diabetes, has a rapid and irreversible onset, and is often accompanied by acute episodes of diabetic ketoacidosis. This article reports a case of immune-related diabetes caused by tislelizumab injection. By analyzing existing literature and clinical cases, the clinical characteristics of immune-related diabetes caused by tislelizumab are summarized, and the potential pathogenesis, treatment, and pharmaceutical care of diabetes caused by immune checkpoint inhibitors are discussed, in order to be vigilant about the immune-related adverse reactions caused by anti-PD-1 immune checkpoint inhibitors in clinical use. ######[AI写代码神器 | 164点数解答 | 2024-10-11 14:52:52]